失代偿期乙型肝炎肝硬化患者发生医院感染临床特点及危险因素分析*

doi:10.3969/j.issn.1672-5069.2020.01.022

摘要/Abstract

摘要： 目的分析失代偿期乙型肝炎肝硬化患者住院期间发生医院感染的临床特点及其危险因素。方法 2016年2月～2018年12月我院收治的失代偿期乙型肝炎肝硬化患者100例,查阅出院病历资料,分析患者发生医院感染的临床特点,应用Logistic 回归分析影响感染发生的因素。结果 100例失代偿期乙型肝炎肝硬化患者在住院期间发生医院感染者25例(25.0%),其中呼吸道感染10例(40.0%),腹膜感染7例(28.0%),肠道感染4例(16.0%);大肠埃希菌感染5例(29.4%),金黄色葡萄球菌感染4例(23.5%),肺炎克雷伯菌感染2例(11.8%),铜绿假单孢菌感染2例(11.8%),肺炎链球菌感染2例(11.8%);单因素分析显示不同性别、是否发生肝性脑病、是否预防性应用抗菌药物患者感染发生率无显著性差异(P>0.05),而不同年龄、住院时间长短、不同肝功能分级、是否行侵入性操作、血清白蛋白和血清胆红素高低、有无腹水和是否应用抗病毒药物患者医院感染发生率差异显著,经多因素回归分析显示年龄≥60岁(OR=4.176,P=0.023)、住院时间≥1月(OR=44.116,P=0.021)、肝功能分级差(OR=5.160,P=0.009)、进行了侵入性操作(OR=5.265,P=0.003)和有腹水(OR=2.921,P=0.033)为影响患者发生院内感染的独立危险因素。结论失代偿期乙型肝炎肝硬化患者在住院期间易发生医院感染,对于感染高危人群应予以高度关注,重视手卫生和适度隔离,以减少院内感染的发生。

关键词: 肝硬化, 乙型肝炎, 医院感染, 临床特点, 危险因素

Abstract: Objective The purpose of this study was to explore the clinical feature of and risk factors for nosocomial infections in patients with hospitalized decompensated hepatitis B liver cirrhosis. Methods 100 patients with decompensated hepatitis B liver cirrhosis were recruited in our hospital between February 2016 and December 2018. The clinical characteristics of patients with nosocomial infection were retrospectively analyzed, and the risk factors for infection were evaluated by Logistic regression analysis. Results Among the 100 patients with decompensated hepatitis B cirrhosis, 25 (25.0%) had nosocomial infection, and among them, 10 (40.0%) were respiratory tract infection, 7 (28.0%) were spontaneous bacteria peritonitis, 4(16.0%) were gut infection; the infected bacteria strains were Escherichia Coli in 5 (29.4%), Staphylococcus Aureus in 4(23.5%), Klebsiella Pneumonia in 2(11.8%), Pseudomonas Aeruginosa in 2(11.8%) and Streptococcus Pneumonia in 2(11.8%); univariate analysis showed that there were no significant differences between male and female patients, or patients with or without hepatic encephalopathy or prophylactic antibiotics(P>0.05), while there were significant differences between young and elderly patients, patients with short or long hospital stay, with different Child-Pugh scores, with or without invasive check-up, with lower serum albumin and bilirubin levels, with or without ascites and with or without anti-viral therapy and multivariate Logistic analysis showed that older than 60 years (OR=4.176, P=0.023), hospital stay longer than one month (OR=44.116,P=0.021), poor Child-Pugh score(OR=5.160,P=0.009), invasive check-up (OR=5.265, P=0.003) and ascites (OR=2.921, P=0.033) were the independent risk factors for nosocomial infections. Conclusion Patients with decompensated hepatitis B liver cirrhosis are prone to nosocomial infection, and clinicians should take risk factors into consideration in this settings to decrease the occurrence of nosocomial infection.

Key words: Liver cirrhosis, Nosocomial infection, Clinical features, Risk factors, Multivariate regression analysis

杨慧玲, 刘小静, 何英利, 杜粉静, 叶峰. 失代偿期乙型肝炎肝硬化患者发生医院感染临床特点及危险因素分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 78-81.

Yang Huiling, Liu Xiaojing, He Yingli, et al. Clinical characteristicsof and risk factors for nosocomial infections in patients with hospitalized decompensated hepatitis B liver cirrhosis[J]. Journal of Practical Hepatology, 2020, 23(1): 78-81.

参考文献

[1] 谢晓, 陆伦根. 乙型肝炎肝硬化抗病毒治疗的进展. 实用肝脏病杂志, 2018, 21(1): 140-144.
[2] Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study. Ann Hepatobiliary Pancreat Surg, 2018, 22(4): 359-366.
[3] Cheng XP, Zhao J, Chen Y, et al. Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis. Eur J Gastroenterol Hepatol, 2016, 28(4): 444-448.
[4] Warren-Gash C, Childs K, Thornton A, et al. Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. Infection, 2017, 45(2): 215-220.
[5] Zhang M, Chen S, Zhu X, et al. Value of red cell distribution width in assessing the severity of hepatitis B virus-related decompensated cirrhosis. Clin Lab, 2017, 63(9): 1467-1474.
[6] Huang YW, Lee CL, Yang SS, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B Patients: A nationwide cohort study. Am J Gastroenterol, 2016, 111(7): 976-985.
[7] Lin CY. Statins and risk of decompensation in hepatitis B virus-related and hepatitis C virus-related cirrhosis: Methodological issues. Hepatology, 2018, 67(3): 1174.
[8] Branchi F, Conti CB, Baccarin A, et al. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol, 2014, 20(40): 14568-14580.
[9] Huang SS, Xie DM, Cai YJ, et al. C-reactive protein-to-albumin ratio is a predictor of hepatitis B virus related decompensated cirrhosis: time-dependent receiver operating characteristics and decision curve analysis. Eur J Gastroenterol Hepatol, 2017, 29(4): 472-480.
[10] Fang X, Liu L, Dong J, et al. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis. J Gastroenterol Hepatol, 2018, 33(4): 774-780.
[11] Mao W, Sun Q, Fan J, et al. AST to platelet ratio index predicts mortality in hospitalized patients with hepatitis B-related decompensated cirrhosis. Medicine (Baltimore), 2016, 95(9): e2946.
[12] Song G, Jiang X, Wang J, et al. Comparative clinical study of laparoscopic and open surgery in children with choledochal cysts. J Cell Mol Med, 2017 21(11): 3023-3043.
[13] Wei L, Kao JH. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Curr Med Res Opin, 2017, 33(3): 495-504.
[14] 史志红,周晓,班志芬. 乙型肝炎肝硬化与酒精性肝硬化患者营养状况评估分析. 实用肝脏病杂志,2018,21(4):629-630.
[15] 李晓萍, 周俊霞. 慢性乙型肝炎合并肝硬化失代偿期患者医院感染的特点及其单因素分析. 肝脏, 2018, 23(11): 1041-1043.
[16] Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology, 2015, 61(6): 1809-1820.
[17] 邓泽润, 郑嵘炅, 唐莉, 等. 失代偿期慢性乙型肝炎肝硬化患者医院感染的相关因素分析及预防策略. 中西医结合肝病杂志, 2017, 27(1): 34-36.
[18] Boettler T, Thimme R. Antiviral therapy in hepatitis B virus-associated liver cirrhosis. Dig Dis, 2015, 33(4): 608-612.
[19] Wang SJ, Yin S, Gu WY, Acute-on-chronic liver failure exists in patients with hepatitis B virus-related decompensated cirrhosis. J Dig Dis, 2018, 19(10): 614-625.
[20] Park J, Jung KS, Lee HW, et al. Effects of entecavir and tenofovir on renal function in patients with hepatitis B virus-related compensated and decompensated cirrhosis. Gut Liver, 2017, 11(6): 828-834.

失代偿期乙型肝炎肝硬化患者发生医院感染临床特点及危险因素分析^*

Clinical characteristicsof and risk factors for nosocomial infections in patients with hospitalized decompensated hepatitis B liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐小元. 解读肝硬化诊治指南难点与新颖之处[J]. 实用肝脏病杂志, 2020, 23(1): 4-6.
[2]	杨可芷, 陆伟, 黄丹, 李秀芬, 王雁冰, 周新兰, 丁蓉蓉, 张占卿. γ-谷氨酰转肽酶/胆碱酯酶比值预测慢性乙型肝炎患者肝纤维化程度的效能评价^*[J]. 实用肝脏病杂志, 2020, 23(1): 14-17.
[3]	叶细容, 吕志红, 江峰, 解育新. 两种超声弹性成像技术诊断慢性乙型肝炎患者肝纤维化价值比较^*[J]. 实用肝脏病杂志, 2020, 23(1): 18-21.
[4]	李永华, 孙延芬, 王佳佳, 李艳颖, 于收. 恩替卡韦联合苦参素治疗慢性乙型肝炎患者疗效及其对外周血辅助性T淋巴细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 22-25.
[5]	丁俊琪, 张偲, 张彬. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎部分应答患者序贯替比夫定治疗疗效观察^*[J]. 实用肝脏病杂志, 2020, 23(1): 26-29.
[6]	王建辉, 郭红丹, 孔晶晶, 武希润. 抗结核药物致药物性肝损伤患者临床特点及其危险因素分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 58-61.
[7]	杨晓玲, 张素梅. SGA、MNA和NRS2002评估失代偿期肝硬化患者营养状态应用价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 70-73.
[8]	王晶晶, 李春涛, 周卫真. 失代偿期乙型肝炎肝硬化患者尿液视黄醇结合蛋白水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 74-77.
[9]	赵平, 黎涛, 谢吉良, 郑波. 早期抗凝干预用于经颈静脉肝内门体静脉支架分流术联合PSE治疗肝硬化患者价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 82-85.
[10]	张冰, 解学军. 酒精性肝硬化患者血CTLA-4和PNPLA3基因多态性及其临床意义分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 86-89.
[11]	陈帅, 杨长青. 门静脉血栓病因及危险因素研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 761-764.
[12]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[13]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[14]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[15]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.